{"data":{"id":"us-in/ic-27-13-38-5","jurisdiction":"us-in","citation":"IC 27-13-38-5","heading":"Drug utilization review programs; confidentiality of enrollees","body":"Sec. 5. The name of an enrollee that is discovered in the course of the drug utilization review program shall remain confidential.","path":["TITLE 27. INSURANCE","ARTICLE 13. HEALTH MAINTENANCE ORGANIZATIONS","Chapter 38. Patient Protection; Drugs and Devices; Drug Utilization Review Program"],"source_url":"https://iga.in.gov/ic/2026/Title_27.html#27-13-38-5","current_through":"2026","vintage":"2026","retrieved_at":"2026-09-25T05:39:04Z","sha256":"1c0995291457ce7c50c8752d4aed6e75e471a60790348cd56aa977b0c3883c92","source_id":"us-in","stale":false,"prev":"us-in/ic-27-13-38-4","next":"us-in/ic-27-13-38-6"},"notice":"GroundRules: Original legal text. Not legal advice."}